DCF Tool


Novanta Inc – Electromedical and Electrotherapeutic Apparatus Manufacturing
novanta (nasdaq: novt) delivers innovations that matter for its medical and advanced industrial oem customers. if you have a passion for solving complex technical problems that lead to breakthrough performance and that enhance people's lives, come join our growing team. here is a sample of the many exciting applications we serve: • innovations that ensure the safety of patients and efficient workflows in hospitals using our novel rfid technology • innovations in additive manufacturing, also known as 3-d metal printing, using our lightning fast lasers and laser beam steering sub-systems • innovations in minimally invasive surgery using our highly reliable insufflators, pumps and visualization systems • innovations in robotics and automation using our precision motors, encoders and drives for superior accuracy • innovations in smartphone production using our fast, accurate lasers and laser beam steering equipment along with our precision motion systems the driving force behind our grow
Analysis Results
Intrinsic Value $134.74
Latest Price $139.46
Relative Value 4% overvalued
Thoughts on this result? Let us know.
Cash Flow (Millions)
Analysis Parameters
New Ticker
Analysis Details
Growth Rate Projection

An exponential growth model was fit to the past cash flow data, giving more weight to more recent years. This model determined a growth rate estimate of 25.8%.

Weighted Average Cost of Capital (WACC)

The calculated WACC is 10.8%. This value is used as the default discount rate.

Value of Future Flows

Assuming a growth rate of 25.8%, the cash flows for the next 5 years are projected.

The present value of each year's flow is adjusted to present value using the discount rate.

Year Future flow (million) Present value (million)
2023 223 202
2024 281 229
2025 353 260
2026 445 295
2027 559 335
Terminal Value

Assuming a growth rate after the projection years of 2.0%, the terminal value of the company would be 6480 million. This corresponds to a present value of 3500 million.

Intrinsic Value Per Share

The total present value of the projected cash flows is 1320 million. Adding in the terminal value gives a total present value of 4820 million.

There are presently 35.8 million outstanding shares, so the intrinsic value per share is 134.74.

Financial Statements

The following data was to determine the past cash flows.

Current Assets 420,519,000
Current Cash 100,105,000
Current Liabilities 164,522,000
Current Debt 5,468,000
Non-Cash Working Capital (NCWC) 161,360,000
Change in NCWC 83,170,000
EBIT 107,463,000
Tax Provision 13,108,000
Depreciation and Amortization 53,158,000
Capital Expenditure -21,113,000
Unlevered Free Cash Flow 206,516,444
Current Assets 373,825,000
Current Cash 117,393,000
Current Liabilities 183,938,000
Current Debt 5,696,000
Non-Cash Working Capital (NCWC) 78,190,000
Change in NCWC -1,928,000
EBIT 82,074,000
Tax Provision 5,841,000
Depreciation and Amortization 43,394,000
Capital Expenditure -22,176,000
Unlevered Free Cash Flow 92,829,601
Current Assets 304,173,000
Current Cash 125,054,000
Current Liabilities 114,229,000
Current Debt 15,228,000
Non-Cash Working Capital (NCWC) 80,118,000
Change in NCWC -15,635,000
EBIT 59,698,000
Tax Provision 3,882,000
Depreciation and Amortization 38,293,000
Capital Expenditure -10,524,000
Unlevered Free Cash Flow 67,044,122
Current Assets 304,512,000
Current Cash 78,944,000
Current Liabilities 134,846,000
Current Debt 5,031,000
Non-Cash Working Capital (NCWC) 95,753,000
Change in NCWC -4,312,000
EBIT 71,856,000
Tax Provision 4,993,000
Depreciation and Amortization 38,280,000
Capital Expenditure -10,743,000
Unlevered Free Cash Flow 87,241,621
Current Assets 281,769,000
Current Cash 82,043,000
Current Liabilities 104,196,000
Current Debt 4,535,000
Non-Cash Working Capital (NCWC) 100,065,000
Change in NCWC 1,292,000
EBIT 79,054,000
Tax Provision 10,207,000
Depreciation and Amortization 37,052,000
Capital Expenditure -14,658,000
Unlevered Free Cash Flow 89,577,229
Current Assets 287,879,000
Current Cash 100,057,000
Current Liabilities 98,168,000
Current Debt 9,119,000
Non-Cash Working Capital (NCWC) 98,773,000
Change in NCWC 30,761,000
EBIT 64,837,000
Tax Provision 13,827,000
Depreciation and Amortization 30,758,000
Capital Expenditure -9,094,000
Unlevered Free Cash Flow 105,486,693
Current Assets 199,250,000
Current Cash 68,108,000
Current Liabilities 70,496,000
Current Debt 7,366,000
Non-Cash Working Capital (NCWC) 68,012,000
Change in NCWC -7,673,000
EBIT 40,508,000
Tax Provision 10,519,000
Depreciation and Amortization 20,357,000
Capital Expenditure -12,442,000
Unlevered Free Cash Flow 27,647,987
Current Assets 185,212,000
Current Cash 59,959,000
Current Liabilities 56,953,000
Current Debt 7,385,000
Non-Cash Working Capital (NCWC) 75,685,000
Change in NCWC -9,782,000
EBIT 37,187,000
Tax Provision 10,394,000
Depreciation and Amortization 19,114,000
Capital Expenditure -5,552,000
Unlevered Free Cash Flow 32,568,371
Current Assets 183,327,000
Current Cash 51,146,000
Current Liabilities 54,214,000
Current Debt 7,500,000
Non-Cash Working Capital (NCWC) 85,467,000
Change in NCWC -785,000
EBIT 29,271,000
Tax Provision -1,006,000
Depreciation and Amortization 23,797,000
Capital Expenditure -5,415,000
Unlevered Free Cash Flow 46,868,000
Current Assets 199,802,000
Current Cash 60,980,000
Current Liabilities 60,070,000
Current Debt 7,500,000
Non-Cash Working Capital (NCWC) 86,252,000
Change in NCWC -9,002,000
EBIT 24,378,000
Tax Provision 5,680,000
Depreciation and Amortization 20,207,000
Capital Expenditure -4,988,000
Unlevered Free Cash Flow 21,065,265
Current Assets 208,468,000
Current Cash 65,788,000
Current Liabilities 54,926,000
Current Debt 7,500,000
Non-Cash Working Capital (NCWC) 95,254,000
Change in NCWC -8,524,000
EBIT 24,405,000
Tax Provision -10,940,000
Depreciation and Amortization 13,676,000
Capital Expenditure -4,308,000
Unlevered Free Cash Flow 25,249,000

This analysis is provided for informational purposes only and does not constitute financial or investing advice. For more information on the advantages and limitations of DCF analysis see background. This information is provided on an "as is" basis. No warranty, expressed or implied, is made regarding accuracy, adequacy, completeness, legality, reliability or usefulness of any information. By using this site you agree that under no circumstances shall Valuation Tools LLC be held liable for any loss or damage caused by information obtained from this website including any articles, data, videos, its social media accounts, or any other materials.